Genovefa A. Papanicolaou
Experienced in Secondary Immunodeficiency (SID)

Dr. Genovefa A. Papanicolaou

Infectious Disease
Memorial Infectious Disease Group
1275 York Ave, 
New York, NY 
Offers Telehealth
34 Years of Experience
Experienced in Secondary Immunodeficiency (SID)
Memorial Infectious Disease Group
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Genovefa Papanicolaou is an Infectious Disease provider in New York, New York. Dr. Papanicolaou has been practicing medicine for over 34 years and is rated as an Experienced provider by MediFind in the treatment of Secondary Immunodeficiency (SID). Her top areas of expertise are Cytomegalovirus Infection, Sepsis, Cytomegalic Inclusion Disease, and Pneumonia.

Her clinical research consists of co-authoring 137 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Secondary Immunodeficiency (SID).

Specialties
Infectious Disease
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

MEMORIAL INFECTIOUS DISEASE GROUP
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: October 17, 2025
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 5 Less Clinical Trials

137 Total Publications

Investigational treatments for cytomegalovirus infection in phase I and II study.
Investigational treatments for cytomegalovirus infection in phase I and II study.
Journal: Expert opinion on investigational drugs
Published: October 21, 2025
Similar Doctors
Joshua D. Nosanchuk
Experienced in Secondary Immunodeficiency (SID)
Dr. Joshua D. Nosanchuk
Infectious Disease
Experienced in Secondary Immunodeficiency (SID)
Dr. Joshua D. Nosanchuk
Infectious Disease

Montefiore At AECOM

1300 Morris Park Avenue, 
Bronx, NY 
 (8.3 miles away)
718-430-2886
Languages Spoken:
English
See accepted insurances

Leadership: Dr. Nosanchuk is an internationally regarded leader in undergraduate medical education, serving most recently as the Senior Associate Dean for Medical Education at Einstein. From 2020-2023, he led a complete revision of the MD program curriculum that included launching new required longitudinal courses on service learning, scholarship, and health systems sciences, and transforming the training phases to a 17-month pre-clinical period followed by 12-months of clerkships and 18-months of individualized professional development. Dr. Nosanchuk has received various education and leadership awrds from Einstein and medical/scientific societies. Dr. Nosanchuk serves on various external education and society committees, including being a member of the Executive Board of the National Board of Medical Examiners. Dr. Nosanchuk is rated as an Advanced provider by MediFind in the treatment of Secondary Immunodeficiency (SID). His top areas of expertise are Paracoccidioidomycosis, Cryptococcosis, Sporotrichosis, and Melioidosis.

Marta L. Feldmesser
Experienced in Secondary Immunodeficiency (SID)
Dr. Marta L. Feldmesser
Infectious Disease
Experienced in Secondary Immunodeficiency (SID)
Dr. Marta L. Feldmesser
Infectious Disease

Northwell Health Physician Partners Internal Medicine At Third Avenue

1421 3rd Avenue, 5th Floor, 
New York, NY 
 (0.8 miles away)
212-434-3427
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marta Feldmesser is an Infectious Disease provider in New York, New York. Dr. Feldmesser is rated as an Experienced provider by MediFind in the treatment of Secondary Immunodeficiency (SID). Her top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Listeriosis, and Pneumonia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papanicolaou's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile